Developing myocardial cells respond to signals from the endocardial layer to form a network of trabeculae that characterize the ventricles of the vertebrate heart. Abnormal myocardial trabeculation results in specific cardiomyopathies in humans and yet trabecular development is poorly understood. We show that trabeculation requires Brg1, a chromatin remodeling protein, to repress ADAMTS1 expression in the endocardium that overlies the developing trabeculae. Repression of ADAMTS1, a secreted matrix metalloproteinase, allows the establishment of an extracellular environment in the cardiac jelly that supports trabecular growth. Later during embryogenesis, ADAMTS1 expression initiates in the endocardium to degrade the cardiac jelly and prevent excessive trabeculation. Thus, the composition of cardiac jelly essential for myocardial morphogenesis is dynamically controlled by ADAMTS1 and its chromatinbased transcriptional regulation. Modification of the intervening microenvironment provides a mechanism by which chromatin regulation within one tissue layer coordinates the morphogenesis of an adjacent layer.
INTRODUCTION
Cardiac progenitor cells of mesoderm origin differentiate into both the myocardium and the endocardium that form the basic layers of the heart, respectively. As development proceeds, these two cell layers interact with each other to form specialized structures of the heart such as heart valves and myocardial trabeculae (reviewed in Harvey, 2002) . Myocardial trabeculation is a key morphogenetic event in heart development that begins at embryonic day E9.0 in mice, when clusters of myocardial cells in the ventricles protrude into the extracellular matrix (cardiac jelly) separating the myocardium from the endocardium. These nascent trabeculae continue to expand, forming long, thin projections. Contiguous with this expansion, ventricular endocardial cells invaginate between the myocardial projections. By E14.5, the ventricular endocardium becomes tightly associated with the myocardial cells as the cardiac jelly dissipates. Finally, the trabeculae largely collapse to thicken the compact layer of myocardium (compaction of myocardium). Excessive trabeculation or a failure of the trabeculae to undergo compaction causes cardiomyopathy and heart failure in humans (Jenni et al., 1999) . Despite its importance, very little is known about the genetic and molecular programs that initiate and terminate trabeculation.
Several studies implicate the importance of the exchange of intercellular signals between the endo-and myocardium during trabeculation. Neuregulin is produced by endocardial cells and acts through the myocardial receptors ErbB2 and ErbB4 to drive myocardial trabeculation (Gassmann et al., 1995; Kramer et al., 1996; Lee et al., 1995) . Conversely, vascular endothelial growth factor (VEGF) and angiopoietin signal from the myocardium to the endocardium to regulate trabeculation (Ferrara et al., 1996; Sato et al., 1995; Suri et al., 1996) . For these signals to be transmitted appropriately, they must traverse the cardiac jelly lying between the endo-and myocardium. Interestingly, both neuregulin and VEGF signaling are modified by extracellular matrix components, suggesting that the establishment of the correct cardiac jelly complement is critical for appropriate receipt of signals between ventricular endo-and myocardium. Consistent with this idea, mice lacking either hyaluronan synthase-2 (Has-2), an enzyme required for production of the mucopolysaccharide hyaluronan, or versican, a chondroitin sulfate proteoglycan, do not develop trabeculae (Camenisch et al., 2000; Mjaatvedt et al., 1998; Yamamura et al., 1997) . The decrease in ventricular cardiac jelly that is observed concomitant with the termination of trabeculation further raises the possibility that active degradation of the cardiac jelly participates in this process. This could be accomplished by a decrease in expression of cardiac jelly components or a change in expression or activity of extracellular matrix regulators. Included in the latter class are the hyaluronidases and members of the matrix metalloproteinase family, notably the ADAMTS (a disintegrin and metalloproteinase with thrombospondin motif) family, whose substrates include Versican (reviewed in Porter et al., 2005) . While both Has-2 and Versican, among other ECM components, and ADAMTS family members exhibit dynamic expression patterns during cardiac development (Camenisch et al., 2000; Henderson and Copp, 1998; Klewer et al., 2006; Thai and Iruela-Arispe, 2002) , the mechanisms of their transcriptional regulation are unknown.
Alteration of chromatin structure provides an important source of gene regulation by determining the accessibility of DNA regulatory elements to transcription factors. Chromatin can be modified noncovalently by the rearrangement of nucleosomes catalyzed by ATP-dependent chromatin remodeling complexes to facilitate both transcriptional activation and repression (Dunaief et al., 1994) . The Brg1-associated-factor (BAF) complex is a ten subunit complex in which the ATPase component is encoded by one of two genes, Brg1 or Brm. Although both genes are broadly expressed, Brg1 null mice show peri-implantation lethality (Bultman et al., 2000) , while Brm null mice are viable (Reyes et al., 1998) . Recent reports suggest that BAF subunits are required for cardiac development. BAF180, a specific subunit of the PBAF form of the BAF complex, regulates cardiac chamber maturation and is required for survival past mid-embryogenesis (Wang et al., 2004) . RNA interference of BAF60c, which is expressed throughout the developing heart, results in severe heart defects including a single ventricle, a poorly developed outflow tract, and no trabeculation (Lickert et al., 2004) . While expression of several myocardial transcripts is reduced in BAF60c knockdown embryos, the molecular basis of these phenotypes is unclear. It is also unknown whether the BAF complex is required in the endocardium, myocardium, or both for cardiac morphogenesis.
We use tissue-specific deletion of Brg1 in both the endocardium and myocardium to study the roles of the BAF complex in each tissue during cardiogenesis. The absence of Brg1 by embryonic day E9.5 produces trabeculation defects when it is deleted from the endocardium but not the myocardium. Neither deletion causes widespread changes in transcription of several key regulators of cardiac development. Instead, the trabeculation defects in the absence of endocardial Brg1 result from derepression of a secreted matrix metalloproteinase, ADAMTS1, which normally only increases in expression later in development to prevent excessive trabeculation. The increase in ADAMTS1 causes premature breakdown of the cardiac jelly and termination of trabeculation, demonstrating that cardiac jelly regulation by endocardial cells coordinates maturation of ventricular myocardium. Further, our data indicate that the BAF complex has a surprisingly specific role in the developing heart after the basic tissue layers are formed. More broadly, we demonstrate that chromatin remodeling can influence tissue morphogenesis through regulation of the microenvironment.
RESULTS

Endothelial Brg1 Is Required for Yolk Sac Vasculogenesis and Primitive Erythropoiesis
To study the function of the BAF complex in endocardial cells, we specifically deleted the core Brg1 subunit throughout the endothelium by crossing mice carrying a loxP-flanked allele of Brg1 (Sumi-Ichinose et al., 1997) with Tie2Cre transgenic mice (Kisanuki et al., 2001) . Brg1 was normally expressed in the nuclei of both myocardial and endocardial cells, as well as all surrounding tissues ( Figure 1A ). In contrast, Brg1 was undetectable in the endocardial cells of Tie2Cre;Brg1 F/F embryos, as marked by expression of the transcription factor NFATc1 (de la Pompa et al., 1998; Ranger et al., 1998) , but remained expressed in all other nonendothelial tissues ( Figure 1B , Figure S2 , see the Supplemental Data available with this article online). This deletion was first evident at E9.0 (data not shown). At E9.5, Tie2Cre;Brg1
embryos were of comparable size to littermate controls ( Figure 1C ). However, they appeared pale due to a decrease in circulating red blood cells caused by defects in yolk sac vasculogenesis and primitive hematopoiesis (Supplemental Data and Figure S1 ). In contrast, the basic pattern of the embryonic vasculature was intact in E9.5 Tie2Cre;Brg1 F/F embryos. By E10.5, Tie2Cre;Brg1 F/F embryos were considerably smaller than their littermates ( Figure 1D ) and none survived to E11.5.
Brg1 Is Required in the Endocardium for Trabeculation
We examined hematoxylin and eosin stained (H&E) sections of Tie2Cre;Brg1 F/F embryos between E9.5 and E10.5 and found defects in trabeculation of the heart ventricles. Normally, nascent myocardial trabeculae are present by E9.5, forming discrete outgrowths of myocardial cells migrating into the cardiac jelly. In Tie2Cre;Brg1 F/F embryos, there was only limited formation of trabeculae at E9.5 ( Figures 1E and 1F ). By E10.5, when trabeculae were normally extensive, Tie2Cre;Brg1 F/F embryos had very sparse trabeculation ( Figure S2 ). We double stained E10.5 embryos for MF20, a myocardial marker, and PECAM, an endocardial marker, to assess the organization of the two cell layers ( Figures 1G and 1H ). Although both cell types were present in Tie2Cre;Brg1 F/F embryos, PECAM-positive endocardial cells did not invaginate around MF20 positive cardiomyocytes outgrowing from the compact layer, consistent with histological observations. We quantified the extent of the trabeculation defect by morphometric measurements of the thickness of individual trabeculae, the total area of trabecular myocardium, and the length of the compact wall in anti-PECAM and anti-MF20 double stained sections. The trabecular thickness was significantly reduced at both E9.75 and E10.5 in Tie2Cre;Brg1 F/F embryos ( Figure 1I , Figure S2 ). At E10.5, the compact layer was also significantly thinner than control embryos ( Figure S2 ). We measured the total degree of trabecular atrophy by normalizing trabecular area to compact wall length. This analysis showed a significant decrease in the extent of trabeculation as well as the size of each trabecular sheet at E9.75 and E10.5 in Tie2Cre;Brg1 F/F embryos ( Figure 1J ). These results demonstrate that Brg1 has critical roles in the endocardium to regulate trabecular development.
Myocardial Brg1 Is Not Required for Trabeculation between E9.5 and E10.5 To investigate the possibility that Brg1 is also required in ventricular myocardium for trabeculation, we deleted Brg1 using the myocardial-expressed SM22aCre transgene (Holtwick et al., 2002; Umans et al., 2007 ; Figure S3 ). Less than 5% of ventricular myocardial cells in E9.5 SM22aCre;Brg1 F/F embryos expressed detectable levels of Brg1, with no evidence of deletion in endocardial cells (Figures 2A and 2B , Figure S3 ). In contrast to Tie2-Cre;Brg1 F/F embryos, SM22aCre;Brg1 F/F embryos had no gross defects in embryonic development up to E10.5 ( Figures 2C and  2D ). H&E staining of sections through the hearts of these embryos demonstrated that trabeculation was normal (Figures 2E and 2F) . Therefore, myocardial BAF complexes do not regulate trabeculation between the time Brg1 was deleted in these mice (between E8.5 and E9.5) and E10.5.
Deletion of Brg1 after E9.0 Does Not Have Widespread Effects on Cardiac Gene Expression
To understand the molecular basis for the myocardial trabeculation defects in Tie2Cre;Brg1 F/F embryos, we examined the expression of myocardial genes important for this process. The expression of Nkx2.5, which is required for trabeculation (Lyons et al., 1995) , and NPPA was decreased in BAF60c RNAi embryos (Lickert et al., 2004) . However, both Nkx2.5 and NPPA were expressed normally in the myocardium of both Tie2Cre;Brg1 F/F ( Figures 3A-3D ) and SM22aCre;Brg1 F/F embryos ( Figure S3 ). The defects in Nkx2.5
and NPPA expression seen in the BAF60c RNAi mice may therefore reflect a requirement for the BAF complex prior to the onset of Brg1 deletion using Tie2Cre or SM22aCre. BMP10, which is also required for trabeculation (Chen et al., 2004) (Ferrara et al., 1996; Meyer and Birchmeier, 1995; Meyer et al., 1997; Sato et al., 1993 Sato et al., , 1995 Suri et al., 1996) . However, they were all expressed normally in E9.5 Tie2Cre;Brg1 F/F embryos ( Figures 3G-3L , Figure S5 ). Recently, the Notch pathway has been shown to be required for trabeculation by regulating expression of neuregulin 
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Chromatin Control of Heart Development (indirectly via ephrinB2) and BMP10 (Grego-Bessa et al., 2007) . Normal expression of these transcripts and the Notch target Hey1 in Tie2Cre;Brg1 F/F embryos ( Figure S5 ) suggests the Notch pathway is not perturbed by the absence of endocardial Brg1. These results indicate that endocardial cells maintained their differentiated state and did not have widespread changes in transcription in the absence of Brg1. Rates of apoptosis and cellular proliferation were also not significantly changed in E9.5 Tie2Cre;Brg1 F/F embryos ( Figure S4 ). Together, these results suggest that the BAF complex has a restricted role in regulating the function rather than differentiation of endocardial cells to control trabecular morphogenesis.
Endocardial Brg1 Is Required for Establishment of Ventricular Cardiac Jelly
Several extracellular matrix (ECM) components, notably hyaluronan and Versican, are required for trabeculation (Camenisch et al., 2000; Yamamura et al., 1997 Figure S5 ). Perlecan, a heparan sulfate proteoglycan required for heart development (Costell et al., 2002) , was also transcribed normally ( Figure S5 ), although Perlecan protein levels were also diminished in ventricular cardiac jelly by E9.75 ( Figure 4G and 4H). Interestingly and as previously reported (Henderson and Copp, 1998) , versican was expressed in myocardium while Has-2 transcripts were found at higher levels in ventricular myocardium compared to the neighboring endocardium. These results are consistent with the observation that the myocardium is the primary source of cardiac jelly components (Manasek et al., 1973) . The normal transcription of Has-2, UGDH, versican, and perlecan suggest that a change in expression of a modulator of ECM, rather than the components themselves, accounts for the ECM deficiency in Tie2Cre;Brg1 F/F embryos.
ADAMTS1 Is Derepressed in the Absence of Endocardial Brg1
We employed a candidate gene approach to identify transcripts whose misregulation in Figure 5C ). A collection of other myocardial and endocardial transcripts were not significantly changed in expression, consistent with our in situ hybridization experiments. An increase in ADAMTS1 expression could account for the subsequent decrease in Versican levels and, indirectly, in the hyaluronan content of the ventricular cardiac jelly as Versican contains hyaluronan-binding domains that may stabilize hyaluronan levels (LeBaron et al., 1992) . Consistent with augmented ADAMTS1 activity, increased staining using an antibody that recognizes a specific cleavage product of Versican (Neo-Versican) arising from ADAMTS activity was observed in E9.25 Tie2Cre;Brg1 F/F embryos prior to further dissipation of Versican levels by E9.5 ( Figures 5D and 5E ). We examined whether repression of ADAMTS1 by Brg1 was a primary effect of Brg1 in endocardial cells using loss-of-function studies of Brg1 in cultured cells. We used human umbilical vein endothelial cells (HUVECs), which express ADAMTS1 (Norata et al., 2004) , as a heterologous source of primary cells. We reduced expression of Brg1 using RNA interference and assayed changes in ADAMTS1 transcript levels. Lentiviral mediated expression of two separate small hairpin RNAs targeting Brg1 produced an increase in ADAMTS1 expression proportionate to the degree of Brg1 transcript knockdown ( Figure 5F ). The most robust knockdown, to 21% of normal Brg1 levels, resulted in a 3-fold increase in endogenous ADAMTS1 transcripts. This result supports our in vivo observations that loss of endocardial 
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Chromatin Control of Heart Development Brg1 is the primary cause of the increase in endocardial ADAMTS1 expression and demonstrates that similar repression of ADAMTS1 by Brg1 occurs in additional endothelial cell types.
Brg1 Directly Associates with the ADAMTS1 Locus in Endothelial Cells
The upregulation of ADAMTS1 in HUVECs and endocardial cells in the absence of Brg1 could represent a secondary effect of misexpression of ADAMTS1 transcriptional regulators or could be accounted for by a direct requirement for the BAF complex in ADAMTS1 repression. To determine whether endogenous Brg1 directly binds the ADAMTS1 locus, we performed chromatin immunoprecipitation assays and quantitative PCR using HUVECs as a source of material. We aligned the mouse, dog, rat, and human genomes to identify conserved regions in the ADAMTS1 locus that may act as sites for Brg1 association ( Figure 6A ). Primer pairs within each of these regions were designed for amplification of DNA from immunoprecipitated chromatin. Antibodies directed against Brg1 precipitated more chromatin fragments from the immediate promoter area (3.73, p < 0.002) and a conserved stretch in the first intron (4.63, p < 0.03) relative to a control anti-GFP antibody ( Figure 6B ). Limited or no enrichment was found for an upstream candidate regulatory site (1.43, p < 0.13) or an unconserved region approximately 30 kb upstream from the promoter ( Figure 6B , data not shown). These results support a model in which the BAF complex directly binds the ADAMTS1 locus near the immediate promoter region to maintain its repression in developing ventricular endocardial cells. We further tested this concept using luciferase reporter assays with regions from the ADAMTS1 locus. We prepared four different constructs that contained either a 2.0 kb immediate promoter fragment or a longer 3.2 kb region that included the second conserved region not bound by Brg1 each with or without the conserved intron region cloned downstream of luciferase. Importantly, the reporter constructs were cloned into Epstein-Barr Virus-derived pREP4 episomal vectors that contain the virus replication origin and express nuclear antigen EBNA-1. These vectors become chromatinized when transfected into mammalian cells and therefore are informative when studying the effects of chromatin remodeling complexes (Liu et al., 2001 ). We transfected each of the four reporter plasmids into SW13 adenocarcinoma cells, which lack both Brg1 and its homolog Brm (Muchardt and Yaniv, 1993) and therefore lack functional BAF complexes, in the presence or absence of a cotransfected Brg1-expressing plasmid. Expressing Brg1 in SW13 cells restores BAF complex function. Lysates from each of the transfection experiments contained between 2.8-and 4.5-fold lower luciferase levels when Brg1 was restored to the cells ( Figure 6C ). These results further support a model of direct repression of ADAMTS1 by Brg1. The site of action is likely through the immediate promoter region (Region 2) of the ADAMTS1 locus, as each of the reporters behaved similarly despite having only that region in common. The results also demonstrate that Brg1 activity, separate from Brm, is necessary and sufficient for repression of ADAMTS1.
ADAMTS1 Derepression Terminates Trabeculation
To investigate whether the increase in ADAMTS1 expression underlies the ECM defects in Tie2Cre;Brg1 F/F embryos, we treated cultured embryos (Chang et al., 2004 ) with GM6001, a broad spectrum inhibitor of matrix metalloproteinases including ADAMTS1 (Shimada et al., 2004) . Wild-type embryos harvested at E9.0 and treated with GM6001 for 36 hr developed relatively normally ( Figures 7A, 7B , 7E, and 7F). Mock-treated Tie2Cre;Brg1 F/F embryos had severe defects in ventricle development, even more so than seen in utero at E10.5. They had an increase in compact layer thickness, no trabeculation, and a near complete absence of Alcian blue staining in the subendocardial space ( Figure 7G ). Tie2Cre;Brg1 F/F embryos treated with GM6001 remained growthretarded and pale, being unchanged in gross appearance ( Figure 7D ). However, they contained Alcian blue-positive material in ventricular cardiac jelly and exhibited a significant recovery of trabeculation ( Figure 7H and 7M ). GM6001-treated Tie2Cre;Brg1 F/F embryos also recovered expression of Versican and hyaluronan in the ventricular cardiac jelly to levels seen in wild-type embryos ( Figures 7I-7L,  7N , and 7O). These results indicate that the increase in ADAMTS1 in Tie2Cre;Brg1 F/F embryos is responsible for the collapse of the ECM through proteolysis of Versican and the subsequent failure of trabeculation. A separate broad-spectrum MMP inhibitor, minocycline (Paemen et al., 1996) , which does not inhibit ADAMTS1 (Rodriguez-Manzaneque et al., 2002), did not rescue trabeculation or cardiac jelly in cultured Tie2Cre;Brg1 Since GM6001 treatment did not rescue the hematopoietic defects in Tie2Cre;Brg1 F/F embryos, as shown by the absence of red blood cells in sections of the cultured embryos ( Figure 7L ), ADAMTS1 derepression does not cause all the phenotypes of Tie2Cre;Brg1 F/F embryos. Consistent with this observation, ADAMTS1 was not derepressed in other endothelial cells in Tie2Cre;Brg1 F/F embryos ( Figure S8 ). This result indicates that Brg1 may have an active and specific role in maintaining ADAMTS1 repression in specific types of endothelial cells, including endocardial cells, rather than a general requirement for establishing the ADAMTS1 transcriptional ground state. This observation raises the question, why does ADAMTS1 need to be repressed in developing ventricular endocardial cells? Interestingly, cardiac expression of ADAMTS1 was low in wild-type embryos until E12.5, when it became highly expressed in the endocardium (marked by Tie1 expression) and persisted through E14.5 (Figures 8A-8F ). Consistent with this observation, the amount of cardiac jelly diminished at E12.5, and was essentially absent by E14.5, when the ventricular endocardium and myocardium were in continuous direct contact (Figures 8G-8I) . Furthermore, the ADAMTS1 substrate, Versican, dramatically decreased in expression in the ventricular cardiac jelly at E12.5, and is essentially absent by E14.5 ( Figures 8J-8L ). Since myocardial trabeculation terminates during the period from E12.5 to E14.5, the increase in ADAMTS1 expression and subsequent dissolution of the cardiac jelly might be required to prevent excessive trabeculation. We tested this idea by examining the phenotype of mice lacking ADAMTS1. While ADAMTS1 À/À mice exhibited approximately 50% embryonic lethality, they were grossly normal at E13.5 ( Figures 8M and 8N ). At E13.5, the ventricles of ADAMTS1 À/À embryos had increased trabecular muscle ( Figures 8O and 8P) . We quantitated the extent of myocardial dysmorphogenesis by morphometric measurements of the left ventricles of 3 ADAMTS1 +/À and 5 ADAMTS1 À/À E13.5 embryos.
ADAMTS1
À/À embryos had a statistically significant increase in the ratio of trabecular area to total ventricle area (0.85 ± 0.07 (C) Episome-based reporter assays using the indicated ADAMTS1 candidate regulatory regions cloned in luciferase expression plasmids cotransfected in SW13 cells with either a control or Brg1-expressing plasmid to restore BAF complexes to the cells. The luciferase activity is graphed relative to a cotransfected constitutive Renilla luciferase control and error bars represent one standard deviation between 3 independent transfections. P values were calculated using unpaired two-tailed Student's t tests.
to 0.58 ± 0.11, p < 0.04; Figure 8Q ). There was no change in the number of trabeculae normalized to the ventricle length (0.04 ± 0.007 to 0.04 ± 0.005, p < 0.83), trabeculae width (14.1 ± 1.2 to 13.7 ± 0.6, arbitrary units, p < 0.67), or compact layer thickness (31.7 ± 2.8 to 33.0 ± 3.2, arbitrary units, p < 0.57; Figure S9 ). These findings suggest that the normal upregulation of ADAMTS1 at E12.5 terminates trabeculation by reconfiguring the extracellular matrix ( Figure 8R ). The transition from repression to activation of ADAMTS1 ensures the proper microenvironment is present for initial support of trabecular growth and then its termination once sufficient trabeculation has occurred.
DISCUSSION
The trabeculation defects in Tie2Cre;Brg1 F/F embryos are caused by derepression of ADAMTS1, which encodes a matrix metalloproteinase that degrades cardiac jelly and prevents /ND groups, n = 8 Tie2Cre;Brg1 F/F /GM6001. P values were determined using Student's t tests.
(N and O) Biotinylated-HABP stained heart sections of Tie2Cre;Brg1 F/F embryos cultured from E9.0 for 36 hr in the presence or absence of GM6001 to mark hyaluronan content (in brown). The sections are counterstained with hematoxylin (blue).
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Chromatin Control of Heart Development trabeculation. ADAMTS1 is a secreted matrix metalloproteinase of hyalectans, including Versican RodriguezManzaneque et al., 2002) . Although ADAMTS1-deficient mice have not been previously examined for cardiac abnormalities, ADAMTS1 has been implicated in cleaving Versican within the endocardial cushion cardiac jelly to facilitate the remodeling of the cushions into atrial and ventricular septa as well as the valve leaflets (Kern et al., 2006) . Versican contains hyaluronan-binding domains (LeBaron et al., 1992) which may be important for establishment of an elaborate glycosaminoglycan-containing network within the cardiac jelly. Therefore, inactivation of Versican by the observed upregulation of ADAMTS1 in Tie2Cre;Brg1 , error bars represent one standard deviation, p < 0.04 by two-sample two-tailed Student's t test). (R) A working model of myocardial trabeculation. Brg1 represses ADAMTS1 in endocardial cells to allow myocardial cells to produce an extracellular environment that supports trabeculation. By E12.5, BAF-complex mediated repression of ADAMTS1 is relieved (by an unknown mechanism, ''X'') dissipating the cardiac jelly and preventing excessive trabeculation. In Tie2Cre;Brg1 F/F embryos, ADAMTS1 is derepressed, causing the cardiac jelly to prematurely break down and disrupting myocardial morphogenesis. embryos could facilitate the degradation of hyaluronan, which then directly leads to collapse of ventricular cardiac jelly. This notion is supported by studies showing that addition of hyaluronidase to whole rat embryo cultures causes collapse of ventricular cardiac jelly and leads to trabeculation defects (Baldwin and Solursh, 1989) . There are several ways how cardiac jelly composition could influence myocardial trabeculation. During trabeculation, both myocardial and endocardial cells must undergo extensive cellular movements to form the long thin projections protruding into the ventricular cavity. Therefore, establishment of an appropriate extracellular milieu that facilitates changes in cell shape, adhesion, or migration may be critical for trabeculation. Second, ECM components could regulate trabeculation by providing a permissive environment for diffusion or posttranslational modification of signaling molecules involved in trabeculation, including Notch (Ferrara et al., 1996) , and angiopoietin (Sato et al., 1993 (Sato et al., , 1995 Suri et al., 1996) . In particular, VEGFR2 signaling in embryonic stem cells is promoted by heparan sulfate proteoglycans produced by adjacent cells (Jakobsson et al., 2006) and heparan sulfate modulates VEGF gradients (Ruhrberg et al., 2002) . Third, certain components of the ECM are active signaling molecules themselves or can directly modify the ability of signaling molecules to act on their receptors. For example, HA binds to the CD44 and LYVE-1 cell receptors, and activates intracellular signaling (Aruffo et al., 1990; Banerji et al., 1999) . HA is also a cofactor for neuregulin signaling (Bourguignon et al., 1997; Camenisch et al., 2002) . Therefore, regulated changes in the microenvironment of the heart ventricle during development could facilitate a developmental transition to terminate cardiac trabeculation independent of the expression of the signaling factors involved.
A specific human congenital cardiomyopathy, termed spongy myocardium, hypertrabeculation, or noncompaction of the myocardium, reflects developmental defects during the trabeculation process. The genetic lesions underlying this disease remain obscure. Hearts of these patients exhibit excessive trabeculation and develop congestive heart failure with the only treatment being a heart transplant. Our observation that premature expression of ADAMTS1 in the absence of endocardial Brg1 prevents trabeculation suggests that the normal increase in endocardial ADAMTS1 expression during development is essential to prevent hypertrabeculation. Interestingly, overexpression of a noncleavable form of Versican in embryonic chick hearts causes a thickening of the right ventricle and possibly hypertrabeculation (Kern et al., 2007) . Here, we show that ADAMTS1 À/À mice, a genotype which is approximately 50% embryonically lethal (Mittaz et al., 2004; Shindo et al., 2000) , develop excessive trabeculation. This result supports a model in which Brg1 represses expression of ADAMTS1 until developmental cues alleviate the repression around E12.5 to facilitate the termination of trabeculation ( Figure 8R ). The increase in ADAMTS1 prevents excessive trabeculation by breaking down ventricular cardiac jelly and altering the microenvironment that supports cellular movements and/or signaling events. Subsequently, the heart develops the thick compact layer that provides the extensive muscular power required in a mature heart. ADAMTS1 À/À embryos that escape embryonic lethality and survive to adulthood do not have apparent noncompaction of the ventricles (data not shown). Therefore, additional cardiac jelly degrading enzymes may cooperate with ADAMTS1 in a partially redundant fashion to terminate trabeculation. Candidates include additional ADAMTS proteins or members of the MMP family, some of which are expressed in the developing heart (Figures S5 and S6; Ratajska and Cleutjens, 2002) and whose substrates also include proteoglycans (reviewed in Flannery, 2006) . A detailed understanding of the roles of cardiac jelly regulators during heart development may help identify candidate genes mutated in families with congenital cardiomyopathy and eventually lead to novel treatments for these diseases.
Activities of chromatin remodeling enzymes are commonly associated with transcriptional activation given their ability to loosen chromatin to facilitate the access of transcription factors and transcriptional machinery. Therefore, although a number of genes have been described as being repressed by the BAF complex (reviewed in de la Serna et al., 2006) , it is surprising to find that a critical function of the BAF complex in developing endocardial cells is as a site-specific transcriptional repressor. While Brg1 directly associates with the ADAMTS1 locus, it remains to be determined how the BAF complex is recruited and how it mediates repression. Since Brg1 remains ubiquitously expressed throughout heart development ( Figure S10 ), changes in Brg1 levels do not account for the normal derepression of ADAMTS1. Therefore, recruitment factors likely provide active regulation of the locus. Alternatively, a change in activity of the BAF complex on ADAMTS1 may lie in a developmental switch in the combinatorial assembly of homologous BAF subunits, which can produce differential BAF complex activities in specific cell types (Lessard et al., 2007) .
Our findings demonstrate an unexpectedly specific role for the BAF complex in maintaining transcriptional repression of ADAMTS1 in developing endocardial cells to establish the appropriate microenvironment for trabeculation of the ventricles. The connection between the BAF complex and regulation of the microenvironment in the developing heart ventricle raises an intriguing possibility that chromatin-based regulation may be a common source for the establishment of extracellular environments. Recent reports indicate an analogous relationship to that between Brg1 and ADAMTS1 exists between the histone deacetylase HDAC7 and MMP10 in the developing vasculature (Chang et al., 2006) and between HDACs and ECM components during worm development (Whetstine et al., 2005) . Furthermore, Brg1 has been implicated in regulating the expression of MMP2 and MMP9 in cultured cells (Ma et al., 2004a (Ma et al., , 2004b . Chromatin regulation may provide a source for signaling specificity by modifying the ability of intercellular signals to be transmitted in a complex environment. This premise may have broad implications given the important roles of chromatin remodeling and the microenvironment in both normal and pathologic settings (Anderson et al., 2006; Bhowmick et al., 2004; Roberts and Orkin, 2004) of tissue growth and differentiation.
EXPERIMENTAL PROCEDURES Mouse Husbandry
All mouse strains were maintained in outbred backgrounds. The targeted null allele of Brg1, Brg1 À (Bultman et al., 2000) , the loxP allele of Brg1, Brg1 F (Indra et al., 2005) , Tie2Cre (Kisanuki et al., 2001) , Sm22aCre (Holtwick et al., 2002) , Rosa26R LacZ (Soriano, 1999) , and ADAMTS1 À (Lee et al., 2006) as embryonic day E0.5, which was confirmed by ultrasonography prior to sacrificing pregnant mice (Chang et al., 2003) and examination of embryo morphology and somite number. Identical styles of crosses were used with Sm22a Cre deletion of Brg1.
Immunostaining
For the antibody staining of paraffin sections we used standard methods, following protocols detailed in the Supplemental Experimental Procedures. The following antibodies were used: anti-Brg1 (G7) mouse monoclonal (Santa Cruz Biotechnology), anti-Brg1 rabbit polyclonal (Chemicon), anti-Brg1 (J1) rabbit polyclonal, anti-NFATc1 (7A6) (BD Biosciences), anti-smooth muscle actin (Sigma), anti-Actinin (Sigma), anti-phospho-Histone H3 (Millipore), antiVersican (Millipore), anti-Perlecan (SPM255) (Santa Cruz Biotechnology), and anti-Neo-Versican (anti-Versican V0/V1 Neo) (Affinity Bioreagents). TUNEL staining was performed using an in situ cell death detection kit (Roche).
Histology
Paraffin sections were prepared as described in the immunostaining section. Following rehydration, the slides were consecutively stained with hematoxylin
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Chromatin Control of Heart Development and eosin (Polysciences), dehydrated, and mounted in Permount (Sigma) prior to imaging. Alcian blue staining was performed using a 1% solution of Alcian blue (pH 2.5) in acetic acid followed by counterstaining with Nuclear Fast Red (Vector Laboratories). Hyaluronan was stained using biotinylated-hyaluronan binding protein (Calbiochem) at 4 mg/ml, HRP-conjugated streptavidin (DAKO), and DAB chromogenic development. The sections were counterstained with hematoxylin.
Trabeculation Quantification
We used a dual-fluorescence confocal image system similar to one previously described (Chen et al., 2004) to visualize, quantitate, and compare the development of trabecular myocardium in Tie2Cre;Brg1 F/F and littermate control embryos. Frozen sections of the embryos were stained with anti-PECAM (BD Biosciences) and anti-MF20 (Developmental Studies Hybridoma Bank) antibodies (described further in the Supplemental Data). The images were captured using LaserSharp software and analyzed with Metamorph (version 6.1).
We measured the thickness of trabecular ridges/sheets (mm), thickness of compact wall (mm), and area of trabecular myocardium normalized by the length of compact wall (mm 2 /mm). For the ADAMTS1 null and heterozygous control mice, a modification of the above protocol was used for morphometric measurements of the hearts. We performed the quantification using images of H&E stained paraffin sections analyzed with Nikon Advanced Elements software. We measured the total number of trabeculae (where the trabecular layer meets the compact layer) normalized to ventricle length, the average thickness of the trabeculae, the average thickness of the compact layer, and the total area of the trabecular sheet normalized to the area of the ventricle (in pixel units). These latter ratios do not represent absolute ratios as the normalization measurements were performed using images taken at a different magnification.
Whole Mount In Situ Hybridization
In situ hybridization assays were based on the protocol described in Wilkinson and Nieto (1993) , with details and modifications described in the Supplemental Experimental Procedures. The plasmid template for the BMP10 in situ probe is described (Chen et al., 2004) .
In Situ Hybridization on Paraffin Sections
Digoxigenin-labeled antisense transcripts were synthesized using plasmid templates (Roche). Plasmids for synthesizing the probes are from the following sources: VEGF-A from Douglas Hanahan (Christofori et al., 1995) , neuregulin from Carmen Birchmeier (Meyer et al., 1997) , Tie2 from Kari Alitalo (Korhonen et al., 1994) , Has-2 from Todd Camenisch (Camenisch et al., 2000) , Tie1, VEGFR2, Nkx2.5, GATA4, ErbB2, Hey1, MEF2C, NPPA, UGDH, versican, perlecan, Irx4, MEST, TIMP3, Hyal1, Hyal2, Hyal3, ADAMTS1, ADAMTS4, ADAMTS5, ADAMTS8, ADAMTS9, ADAMTS18, MMP1, MMP2, MMP3, MMP9, MMP13 , and fibulin1 from Open Biosystems. All plasmids were confirmed by sequencing. Details for probe hybridization and visualization are included in the Supplemental Experimental Procedures.
RT-PCR and Quantitative RT-PCR
Whole hearts were dissected from E9.5 embryos. The hearts were disrupted in Trizol (Invitrogen) and RNA was purified using standard methods. One hundred and fifty nanograms of total RNA from each sample was used as a template to prepare cDNA using the Superscript III reverse transcription system (Invitrogen). In the case of HUVECs, RNA was isolated using a Trizol-based method and 500 ng of RNA was used for cDNA synthesis. Quantitative PCR to measure transcript content in the individual samples was performed using primers and is described in the Supplemental Experimental Procedures.
Lentivirus Production and RNA Interference Lentivirus were produced in 293T cells following protocols of the Didier Trono lab by cotransfecting them with packaging and envelope plasmids and pGIPZ transfer vectors for shRNA expression (Open Biosystems). Two separate plasmids expressing shRNAs targeting human Brg1 were used while the control pGIPZ vector contains a nonsilencing shRNA. Two days posttransfection of the 293T cells, the media was isolated, filtered, and concentrated using a 100k MW cutoff centrifugal filter unit (Millipore). This viral concentrate was used for transduction of HUVECs. The cells were cultured for 5 d, at which point most of the cells expressed GFP, indicating a high rate of infection. RNA was prepared using Trizol extractions and then used for cDNA synthesis. Expression levels were determined using quantitative RT-PCR as described above.
Chromatin Immunoprecipitations
HUVECs were cultured to approximately 75% confluency on six 15 cm plates and harvested using reagents and methods from a chromatin immunoprecipitation kit (Upstate) with modifications and details described in the Supplemental Experimental Procedures. Chromatin was prepared and immunoprecipitated using the J1 anti-Brg1 antibody (Wang et al., 1996) and an anti-GFP (Invitrogen) antibody as an isotype-matched negative control. Following washes, DNA was retrieved and used for quantitative PCR using primers and methods described in the Supplemental Experimental Procedures.
Reporter Assays
Reporter plasmids were constructed by cloning PCR amplified regions of the mouse ADAMTS1 locus into the episomal pREP4-Luc plasmid (Liu et al., 2001) . These vectors, along with an episomal Renilla-luciferase plasmid (pREP7-RL) to normalize for transfection efficiency and a plasmid expressing human Brg1 or a matching empty vector plasmid, were transfected into SW13 cells using lipofectamine 2000 (Invitrogen). The cells were cultured for 2 d and harvested for luciferase assay using the dual luciferase assay kit (Promega).
Whole Embryo Culture
Whole embryo cultures were performed as described (Chang et al., 2004) . Embryos were isolated intact in their yolk sacs at E9.0 and cultured for 36 hr in the presence of either 20 mM GM6001 (Calbiochem), 20 mM Minocycline (Sigma), or an equivalent amount of DMSO alone. The yolk sacs were used for genotyping and the embryos harvested for histological analysis.
Supplemental Data
Supplemental Data include Supplemental Experimental Procedures and ten figures and are available with this article online at http://www. developmentalcell.com/cgi/content/full/14/2/298/DC1/.
